Pricing Log in Create free account
Saturday 17 October 2026 Export SOPH’s income statement to Excel — free account

SOPHiA GENETICS SA

SOPH Healthcare Health Information Services

SOPHiA GENETICS SA’s revenue for fiscal 2025 (year ended December 2025) was $77.3 million, up 18.6% from fiscal 2024. In the quarter to June 2026, revenue grew 27.2%, EPS grew 9.88%, free cash flow grew 6.50% and total debt rose 1.12%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

6.73 0.56 −7.68%
Market cap
$620.6M
P/E
0.0×
Fwd P/E
−5.5×
Dividend yield
—
F-score
2/9
Altman Z
−3.43
Beneish M
−3.30
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.10
Total sells 5.18
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — 1 — — — —
Sell — — — — 9 33 12 9 14 14 7 12
Insider Ownership 16.36%

Capital & Financial Ratios $m

Market Cap 620.58
Revenue 86.17
Net Income (80.30)
Free Cash Flow (41.21)
Net Debt (59.67)
Current Ratio 2.69 (at or above 1.5: strong)
Debt/Equity 0.58
P/E ratio 0.00
Fwd P/E (5.51) (negative: loss-making)
P/S ratio 5.77
P/B ratio 5.98
Past 5Y EPS Growth —
This Y EPS Growth 19.83% (at or above 15%: strong)
Next Y EPS Growth 33.26% (at or above 15%: strong)
Next Y revenue growth 23.24% (at or above 10%: strong)
Next 5Y EPS Growth 32.33% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 5.1×, against a ten-year median of 3.2×; over the ten years it ranged from −0.9× in 2022 to 26.6× in 2021.
P/S against its own 10 years 75.29%
10-year low 10-year high
P/B against its own 10 years 83.27%
10-year low 10-year high
EV/Sales against its own 10 years 80.66%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 123 80 70 108
Receivables 14 7 15 14
Inventory 6 6 6 7
Other 5 6 7 8
148 99 99 137
2023 2024 2025 Q'26
Payables 5 5 9 12
ST’ Debt — — — —
Other — 0 1 2
36 27 51 51

Compound Annual Growth %

10y 5y 3y
Sales — 22.16% 17.56%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (14.05%) (38.24%)

Revenue $m

Mar Jun Sep Dec Year
’26 22 23 — — —
’25 18 18 19 22 77
’24 16 16 16 18 65
’23 14 15 16 17 62
’22 11 12 12 13 48
’21 9 10 10 11 40
’20 7 6 7 8 28
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (15) (8) — — —
’25 (11) (8) (9) (8) (36)
’24 (15) (10) (9) (11) (45)
’23 (15) (10) (12) (11) (49)
’22 (17) (20) (23) (10) (70)
’21 (10) (16) (16) (15) (58)
’20 (7) (5) (10) (9) (32)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (16) (8) — — —
’25 (11) (8) (9) (8) (37)
’24 (15) (11) (9) (11) (45)
’23 (16) (12) (13) (11) (50)
’22 (18) (21) (24) (11) (75)
’21 (10) (17) (18) (16) (61)
’20 (7) (5) (11) (10) (32)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.27) (0.30) — — —
’25 (0.26) (0.33) (0.30) (0.28) (1.17)
’24 (0.21) (0.23) (0.28) (0.23) (0.95)
’23 (0.31) (0.33) (0.21) (0.37) (1.22)
’22 (0.40) (0.39) (0.36) (0.22) (1.36)
’21 (0.26) (0.38) (0.35) (0.33) (1.33)
’20 (0.27) (0.20) (0.24) (0.22) (0.93)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — — 11.71 1.69 1.85 2.70 2.58

Analyst estimates 2026–2028

Powerpack
High — — — — — 19.80 15.83 5.77 7.37 5.30
People
People Employees — — — — 462 518 466 449 423 415
Revenue/emp, $m — — — 0.00 0.06 0.08 0.10 0.14 0.15 0.19
Income, $m
Income, $m Revenue — — — 25 28 40 48 62 65 77
Gross margin, % — — — 70.30 62.29 62.35 65.71 68.80 67.42 67.40
EBT — — — (34) (41) (74) (88) (78) (61) (77)
EBT margin, % — — — (132.60) (145.16) (181.72) (184.16) (125.85) (94.01) (100.28)
Net income — 0 — (34) (41) (74) (88) (78) (61) (77)
Depreciation — — — 2 2 4 6 8 9 10
Per share, $
Per share, $ Revenue — — — 0.67 0.67 0.73 0.74 0.96 0.99 1.14
Earnings — — — (0.90) (0.93) (1.33) (1.36) (1.22) (0.95) (1.17)
Cash flow — — — (0.84) (0.75) (1.05) (1.09) (0.75) (0.67) (0.53)
Capex — — — (0.08) (0.02) (0.05) (0.07) (0.03) (0.01) (0.01)
Free cash flow — — — (0.92) (0.77) (1.10) (1.16) (0.78) (0.68) (0.54)
Book value — — — 0.59 2.37 4.98 3.12 2.34 1.46 0.70
Shares, m — — — 38 42 55 64 65 66 68
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S — — — 24.00 24.00 19.28 3.03 5.01 3.11 4.08
P/B — — — 11.53 11.53 2.83 0.72 2.07 2.10 6.69
EV/Sales — — — 22.24 22.24 13.04 (0.39) 3.30 2.11 3.81
EV/FCF — — — (15.91) (15.91) (8.68) 0.25 (4.09) (3.06) (8.04)
Cash, $m
Cash, $m Operating cash flow — — — (32) (32) (58) (70) (49) (45) (36)
Capex — — — (3) (1) (3) (5) (2) 0 (1)
Free cash flow — — — (35) (32) (61) (75) (50) (45) (37)
Balance, $m
Balance, $m Working capital — — — 15 88 254 169 112 73 49
Total debt — — — 4 3 11 14 — 13 48
Net debt — — — (15) (94) (254) (165) (123) (67) (23)
Shareholders’ equity — — — 22 101 275 200 151 96 47
Returns, %
Returns, % ROA — — — (130.83) (42.81) (32.58) (31.01) (35.10) (34.58) (49.63)
ROIC — — — (263.58) (359.77) (209.50) (154.31) (165.89) (141.03) (180.23)
ROE — — — (55.05) (64.09) (39.20) (36.78) (44.93) (50.41) (110.00)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

SOPHiA GENETICS SA vs peers in Health Information Services (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
HSTM HealthStream, Inc. $1.0B 46.0× 34.4× +12.55% (above 0%: growing) +27.78% (above 0%: growing) +362.71% (above 0%: growing) 65.35% 9.94% Compare
PHR Phreesia, Inc. $685.3M 64.4× 23.5× +10.41% (above 0%: growing) +200.00% (above 0%: growing) +43.51% (above 0%: growing) 66.64% 5.88% Compare
MDRX Veradigm Inc. $654.5M — (loss-making) — (loss-making) −9.74% (below 0%: shrinking) n/m −66.33% (below 0%: shrinking) 50.53% (37.41%) Compare
SOPH SOPHiA GENETICS SA $620.6M — (loss-making) — (loss-making) +27.22% (above 0%: growing) n/m +6.50% (above 0%: growing) 64.61% (86.03%)
WEAV Weave Communications, Inc. $594.5M — (loss-making) — (loss-making) +15.52% (above 0%: growing) n/m +94.33% (above 0%: growing) 72.03% (6.49%) Compare
EVH Evolent Health, Inc $550.6M — (loss-making) — (loss-making) +46.86% (above 0%: growing) n/m +58.67% (above 0%: growing) 12.39% (1.47%) Compare
NRC National Research Corporation $466.9M 80.6× 4.9× +3.98% (above 0%: growing) n/m +101.49% (above 0%: growing) 61.67% (9.15%) Compare
CTEV Claritev Corporation $404.4M — (loss-making) — (loss-making) +6.59% (above 0%: growing) n/m +49.10% (above 0%: growing) 73.72% 9.09% Compare
CARL Carlsmed, Inc. $380.9M — (loss-making) — (loss-making) +56.75% (above 0%: growing) n/m −6.84% (below 0%: shrinking) 76.78% (58.27%) Compare
Median of peers $572.6M 64.4× 23.5× +11.48% — +53.89% 66.00% (3.98%)

All 51 Health Information Services stocks →

SOPHiA GENETICS SA (SOPH) key facts

  • Strength: SOPHiA GENETICS SA’s revenue for fiscal 2025 (year ended December 2025) was $77.3 million, up 18.6% from fiscal 2024.
  • SOPHiA GENETICS SA (SOPH) is a Health Information Services company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, SOPH traded at $6.73, a market capitalization of $620.6 million.
  • Return on equity was −110.0% and debt-to-equity 0.58.
  • Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −3.43 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

SOPHiA GENETICS SA (SOPH) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/SOPH · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com